Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Icotinib in High-Risk Stage I EGFRm NSCLC
NCT05514314Phase 2Unknown
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of icotinib in non-small cell lung cancer (NSCLC). Primary endpoint: Recurrence-Free Survival at 10 years. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05514314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514314.